MedPath

Felcisetrag

Generic Name
Felcisetrag
Drug Type
Small Molecule
Chemical Formula
C25H37N5O3
CAS Number
916075-84-8
Unique Ingredient Identifier
35F0Y2W16Q

Overview

Felcisetrag (TD-8954) has been used in trials studying the treatment of Enteral Feeding Intolerance and Gastrointestinal Motility Disorder.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants
2019/03/12
NCT03870555
Phase 1
Completed
Millennium Pharmaceuticals, Inc.
A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery
2019/02/01
NCT03827655
Phase 2
Completed
Takeda
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
2018/03/27
NCT03477903
Phase 2
Terminated
Millennium Pharmaceuticals, Inc.
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954
2017/09/28
NCT03296787
Phase 1
Completed
Takeda
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
2017/09/13
NCT03281577
Phase 2
Completed
Takeda
A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954
2017/09/11
NCT03277274
Phase 1
Completed
Takeda
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants
2017/06/01
NCT03173170
Phase 1
Completed
Takeda
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance
2013/09/30
NCT01953081
Phase 1
Completed
Takeda
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
2012/07/19
NCT01644240
Phase 1
Terminated
Theravance Biopharma

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy